Exelixis Files Zanzalintinib With FDA As Valuation Signals Upside Potential [Yahoo! Finance]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Yahoo! Finance
Exelixis (NasdaqGS:EXEL) has submitted an FDA application for zanzalintinib, its next generation cancer therapy, in metastatic colorectal cancer. The filing covers use of zanzalintinib in combination with Roche's Tecentriq. The company is preparing for several major clinical trial milestones expected in 2026, including phase 3 and other late stage readouts. For you as an investor, this update sits on top of Exelixis' existing oncology drug portfolio and its focus on targeted cancer treatments. The tie up with Tecentriq brings an immunotherapy partner into the mix, which can matter for how physicians ultimately use new regimens in real world practice. Looking ahead, the key issues to watch are the FDA review process for zanzalintinib and the timing and design of the 2026 phase 3 milestones. How those trials are structured, and whether they meet their clinical goals, could influence Exelixis' pipeline priorities and its position among cancer drug developers. Stay updated on t
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Exelixis (NASDAQ:EXEL) was given a new $49.00 price target on by analysts at Morgan Stanley.MarketBeat
- Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer [Yahoo! Finance]Yahoo! Finance
- Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal CancerBusiness Wire
- Alterome Therapeutics Appoints Leo Faoro, MD, MBA, as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Assessing Exelixis (EXEL) Valuation After Recent Share Price Volatility [Yahoo! Finance]Yahoo! Finance
EXEL
Earnings
- 11/4/25 - Beat
EXEL
Sec Filings
- 1/16/26 - Form 4
- 1/16/26 - Form 4
- 1/16/26 - Form 4
- EXEL's page on the SEC website